Navigation Links
AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

ies (range 1 - 4) and 81% were previously treated with bortezomib plus dexamethasone); - 98% of patients were previously treated with dexamethasone; - 94% of patients were previously treated with lenalidomide (Revlimid(R)) and/or thalidomide (Thalomid(R)); and - 58% of patients had prior stem cell transplant.

Overall Response Rate (ORR), defined as the percentage of patients achieving a complete, partial or minor response (CR, PR or MR), was the primary endpoint, with Time to Progression (TTP), Progression-Free Survival (PFS), Overall Survival (OS) and Safety as secondary endpoints.

Seventy-three patients were evaluable for efficacy. Evaluable patients are defined as those patients who had received at least two cycles of therapy on the combination of perifosine with bortezomib. Of the 73 evaluable patients, 53 patients (73%) were previously refractory to bortezomib (defined as progression on or within 60 days of treatment to a bortezomib-based regimen), including 44 patients who were refractory to the combination of bortezomib + dexamethasone. Twenty evaluable patients (27%) were relapsed to a prior bortezomib-based regimen. Best response for all 73 evaluable patients was as follows:

    -------------------------------------------------------------------------
    Evaluable Patients   CR/nCR*   PR         MR        ORR       SD**
    -------------------------------------------------------------------------
    All Evaluable
    Patients
     (n=73)   3   4%   13   18%   14   19%   30   41%   30   41%
    -------------------------------------------------------------------------
    Bortezomib Relapsed
     (n=20)   2  10%    7   35%    4   20%   13   65%    7   35%
    -------------------------------------------------------------------------
    Bortezomib
     Refractory
     (n=53)   1   2%    6   11%   10   19%   17   32%   23   43%
    --------------------------------------------------------------
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares proposed ... common shares (including shares of unvested restricted stock). On June 29, 2015, the last ... of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The tender ...
(Date:6/30/2015)... June 30, 2015  The Dr. Samadi Prostate Cancer Center ... offering a full suite of new genetic testing methods for ... for diagnosing prostate cancer. Dr. Samadi,s ... tests for assessing the risk and optimizing the diagnosis of ... very excited to now offer these revolutionary genetic tests to ...
(Date:6/29/2015)... 30, 2015   Pharnext SAS today announced that ... the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented ... Peripheral Nerve Society (PNS) Biennial Meeting at the Quebec Congress ... 27 - July 2, 2015. At Poster Viewing ... 1, 5p.m. to 7p.m. EDT: Poster 23: ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
... U.S. District Court for the Western District of Wisconsin ... , preventing the pharmaceutical company from further sales or use ... held by Innogenetics , a biopharmaceutical company based in ... a $7 million damage verdict against Abbott. In September of ...
... - How does a tech-based economy help parts of ... Valley or to attract millions of dollars in medical ... of Imago Scientific Instruments in suburban Madison. , ... nanotechnology , which is unlocking the chemical, electrical, and ...
... $140 million biomedical research facility will advance both translational ... Medical College of Wisconsin and Children's Hospital ... Doyle and Milwaukee County Executive Scott Walker ... Children's Research Institute dedicated the 298,000 square-foot-facility, a ...
Cached Biology Technology:How a healthy tech-based economy helps others in Wisconsin 2How a healthy tech-based economy helps others in Wisconsin 3How a healthy tech-based economy helps others in Wisconsin 4Medical College dedicates $140M research facility 2
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
(Date:6/17/2015)... und GERMANTOWN, Maryland , June 17, ... ®   Produktlinie mit DNA-Tests verbessert den Analyseprozess ... QGEN ; Frankfurt Prime Standard: QIA) hat heute ... der Produktlinie Investigator ® ... eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke bieten ...
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... out on low early bird rates for the premier bone ... (IOF-ECCEO12), from March 21-24, 2012 will be held in in ... early bird rates: register by December 9, 2011 at ... international experts and key thought leaders... Plenary lectures:, ...
... treated with anticoagulants to thin the blood, but this ... have their blood tested regularly. Researchers at the Sahlgrenska ... of Technology have now devised a new method that ... fibrillation, or irregular heartbeat, is a very common heart ...
... available in German . , GLORIA is ... the Atmosphere". This complicated name refers to a novel type ... gases into its spectral colors. This allows for a very ... was developed by Forschungszentrum Jlich and Karlsruhe Institute of Technology ...
Cached Biology News:Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux 2New method for safer dosing of anticoagulants 2GLORIA: Unique climate research experiment worldwide 2GLORIA: Unique climate research experiment worldwide 3
MOUSE ANTI DUCK IgY LIGHT CHAIN...
Kit for Detection of Mitochondrial Membrane Potential...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
...
Biology Products: